UIC UNIVERSITY OF ILLINOIS AT CHICAGO
College of Medicine
Department of Pharmacology
Toxicology Research Laboratory

In collaboration with leading scientists
of the **NCI, NIAID** and **FDA**
ANNOUNCES

2006 INTERNATIONAL CONFERENCE

FRONTIERS OF PHARMACOLOGY AND TOXICOLOGY: Addressing Translational Research in Efficacy and Safety of New Medicines

August 28 – 31, 2006
The Renaissance Chicago Hotel
Chicago, Illinois

ALSO OFFERING TWO PRE-CONFERENCE COURSES

Toxicology in Drug Development

and

Fundamentals of Developmental and Reproductive Toxicology

August 26 – 27, 2006

CALL FOR ABSTRACTS

Oral Presentations – Deadline: April 1, 2006
Poster Presentations – Deadline: May 1, 2006

Conference Website: www.uic.edu/labs/tox/frontiers

MEMBERS OF ORGANIZING COMMITTEE /

Joseph E. Tomaszewski, Ph.D., Deputy Director, Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute

James A. Crowell, Ph.D., D.A.B.T., Chief, Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute

Alexander Lyubimov, M.D., Ph.D., D.A.B.T., Director, Toxicology Research Laboratory, University of Illinois at Chicago

David Jacobson-Kram, Ph.D., Associate Director for Pharmacology and Toxicology, Center for Drug Evaluation and Research, US FDA

Bert W. Maidment, Ph.D., Associate Director, Product Development, NIAID/DAIT

Richard J. Hatchett, M.D., Associate Director, Radiation Countermeasures Research and Emergency Preparedness, NIAID/DAIT

Judith A. Hewitt, Ph.D., Office of Biodefense Research Affairs, Division of Microbiology & Infectious Diseases, NIAID, Bethesda, MD

Asrar B. Malik, Ph.D., Distinguished Professor and Head, Department of Pharmacology, University of Illinois at Chicago

David R. Cassatt, Ph.D., Program Officer, NIAID/DAIT

Ronald D. Hood, Ph.D., Principal, Ronald D. Hood & Associates, Professor Emeritus of Biological Sciences, University of Alabama

Faith Davis, Ph.D., Professor, Division of Epidemiology and Biostatistics, University of Illinois at Chicago

Wanda M. Haschek-Hock, B.V.Sc., Ph.D., D.A.C.V.P., D.A.B.T., Professor of Pathobiology, University of Illinois Urbana-Champaign

Mark Hull, M.D., Ph.D., Professor, Leeds Institute of Molecular Medicine, University of Leeds, St. James University Hospital, Leeds, UK

Thomas Macvittie, Ph.D., Professor, University of Maryland, Baltimore

Eric Blomme, Ph.D., D.V.M., D.A.C.V.P., Abbott Laboratories, Chicago IL

Mark Abdy, D.V.M., Ph.D., US Food and Drug Administration

William G. Nelson, M.D. Ph.D., Professor, John Hopkins University, Baltimore

Hajime Ohigashi, Ph.D., Graduate School of Agriculture, Kyoto University, Kyoto, Japan

Young-Joon Surh, Ph.D., Chief & Professor, National Research Laboratory of Molecular Carcinogenesis and Chemoprevention, Seoul National University, Korea

Clarissa Gerhäuser, Ph.D., German Cancer Research Center, Heidelberg, Germany

Moray Campbell, Ph.D., Institute of Biomedical Research, Medical School, University of Birmingham, United Kingdom

Caroline Lee, Ph.D., Principal Investigator, Division of Medical Sciences, National Cancer Center, Singapore

Raffaella Giavazzi, Ph.D., Head, Laboratory of Biology & Treatment of Metastasis, Mario Negri Institute for Pharmacological Research, Bergamo, Italy

Clive D. Morris, Ph.D., Medical Science Director Oncology, Astra Zeneca, UK

Melinda G. Hollingshead, D.V.M., Ph.D., Chief, NCI-FCRDC

Beverly A. Teicher, Ph.D., Vice President, Oncology Research Genzyme Corporation, Framingham, MA

INVITED SPEAKERS / SESSION CHAIRS

Angelika Burger, Ph.D., Director, Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine

Hasan Mukhtar, Ph.D., Vice-Chair and Director of Research, Department of Dermatology, Medical School, University of Wisconsin

Piet A. van den Brandt, Ph.D., Nutrition and Toxicology Research Institute, Maastricht, Maastricht University, Maastricht, The Netherlands

Shivendra V. Singh, Ph.D., Professor, Cancer Center, University of Pittsburgh

Roderick H. Dashwood, Ph.D., Professor and Chief, Cancer Chemoprotection Program, Oregon State University

Rajesh Agarwal, Ph.D., Professor, School of Pharmacy, University of Colorado Health Sciences Center

Gary Stoner, Ph.D., College of Medicine and Public Health, Department of Internal Medicine, Ohio State University

Jean-Charles Soria Ph.D., Division of Cancer Medicine, Institute Gustave Roussy, Paris France

Keith A. Rodvold, Pharm. D., Professor, Department of Pharmacy Practice, University of Illinois at Chicago

Fritz H. Schröder, Ph.D., Department of Urology, Erasmus MC, University Medical Center Rotterdam, The Netherlands

Dai Nakae, M.D., Ph.D., Head, Department of Pathology, Sasaki Institute, Sasaki Foundation, Japan

Sanjay Gupta, Ph.D., Department of Urology, Case Western Reserve University, Cleveland, Ohio

David Kerstin, Ph.D., Vice-President, Center for Cancer Research at the Israelitic Hospital, Hamburg, Germany

Michael A. White, Ph.D., Associate Professor, Department of Cell Biology, UT Southwestern Medical Center, Dallas, TX

Myrtle Davis, D.V.M., Ph.D., Investigative Toxicology, Lilly Research Laboratories, Greenfield, IN

Edward A. Sausville, M.D., Ph.D., F.A.C.P., Associate Director, Greenebaum Cancer Center, University of Maryland, Baltimore, MD

James A. Radosevich, Ph.D., Professor, Center for Molecular Biology of Oral Diseases, University of Illinois at Chicago

Richard Minshall, Ph.D., Assistant Professor of Pharmacology, University of Illinois at Chicago

Hayat Onyuksel, Ph.D., Professor of Pharmaceutics and Bioengineering, University of Illinois at Chicago

Vladimir Muzykantov, M.D., Ph.D., Director, Targeted Therapeutics Program, Institute of Translational Medicine & Therapeutics, University of Pennsylvania

Gail S. Prins, Ph.D., Professor of Physiology, Department of Urology, University of Illinois at Chicago

Robert H Costa, Ph.D., Professor, Assistant Director of the GI Cancer Program, University of Illinois at Chicago

SPONSORS:

TOXICOLOGY RESEARCH LABORATORY
DEPARTMENT OF PHARMACOLOGY and CANCER CENTER
UNIVERSITY OF ILLINOIS AT CHICAGO

SOCIETY OF TOXICOLOGY

CORPORATE SPONSORS:

ELSEVIER

LABCAT

APPLIED BIOSYSTEMS

WATERS CORPORATION

CONFERENCE DESCRIPTION

The conference will provide an outstanding opportunity for presentations from leading scientists on the most recent advances in pharmacology and toxicology-related topics, with an emphasis on translational research. This meeting will bring together foremost experts from the UK, Germany, the Netherlands, Italy, France, Japan, Singapore, Korea, and other countries, as well as from throughout the United States, for discussion of the most recent advances in the efficacy and safety of new medicines. The conference will allow a variety of specialists from government, academia and industry, including clinicians, to share cutting-edge data in the fields of new drug development, cancer prevention and therapy, and biodefense in order to translate their research into clinical practice. This information will address issues related to the diagnosis, prevention and treatment of cancer, radiation damage, and infectious and other diseases. This conference will blend state-of-the-art panel discussions and plenary session presentations from invited speakers, as well as many short presentations and posters carefully selected from submitted abstracts. This will give younger scientists and students an excellent opportunity to present, discuss and publish their results. The Conference program and abstracts will be published in a peer-reviewed special issue of the Elsevier journal "Chemico-Biological Interactions."

Conference Main Themes:

- Cancer Treatment and Diagnosis
- Cancer Chemoprevention
- Animal Models for Cancer Therapy and Prevention
- Translational Research in Organ-Specific Cancers
- Frontiers of Drug Discovery and Development
- Medical Countermeasures Against Radiological and Nuclear Threats
- Efficacy and Safety of New Drugs for Emerging Infectious Diseases and Biodefense
- Clinical Trials

Oral and poster presentations in other fields of Pharmacology and Toxicology will also be welcomed.

INSTRUCTIONS FOR AUTHORS can be accessed at the conference website. (www.uic.edu/labs/tox/frontiers)

ABSTRACTS will be evaluated as they are received. The submission deadline is **April 1, 2006**, for inclusion in a session for oral presentations, and no later than **May 1, 2006**, for publication in a special peer-reviewed issue of "Chemico-Biological Interactions." Space for oral and poster presentations is limited. The UIC Department of Pharmacology will **award prizes** to students for best presentation: **1st – $500, 2nd – $300 and 3rd – $200.**

Organized by the **Toxicology Research Laboratory (TRL), Department of Pharmacology, College of Medicine, University of Illinois at Chicago** in collaboration with two departments (DCTD and DCP) of the **National Cancer Institute (NCI) and National Institute of Allergy and Infectious Diseases (NIAID).**

FOR MORE INFORMATION ABOUT THE CONFERENCE CONTACT:

Conference Organizer: **Dr. Alexander Lyubimov**, TRL Director (312) 996-9185 or **Mary Ann Borjal**, Assistant to the Director at (312) 996-5177

Email: trlab@uic.edu

CONFERENCE OVERVIEW

MONDAY, AUGUST 28

PLENARY SESSION: CANCER TREATMENT AND DIAGNOSIS
Chairperson: **Joseph E. Tomaszewski**, Ph.D., Deputy Director, (DCTD), NCI

SPECIAL SYMPOSIA:
ANIMAL MODELS FOR CANCER THERAPY AND PREVENTION
Chairperson: **Melinda Hollingshead**, D.V.M., Ph.D., NCI

EFFICACY AND SAFETY OF NEW DRUGS FOR EMERGING INFECTIOUS DISEASES AND BIODEFENSE
Chairperson: **Mark Abdy**, D.V.M., Ph.D., FDA

POSTER SESSIONS

TUESDAY, AUGUST 29

PLENARY SESSION: CANCER CHEMOPREVENTION
Chairperson: **James A. Crowell,** Ph.D., D.A.B.T., NCI

SPECIAL SYMPOSIUM: MEDICAL COUNTERMEASURES AGAINST RADIOLOGICAL AND NUCLEAR THREATS
Chairpersons: **Thomas Macvittie**, Ph.D., Professor, UMB; **Bert W. Maidment**, Ph.D., Associate Director, Product Development, NIAID/DAIT

PANEL DISCUSSION: NEW POLICIES AND APPROACHES FOR DRUG DEVELOPMENT AND SAFETY ASSESSMENT: FDA Perspective
Moderator: **David Jacobson-Kram**, Ph.D., D.A.B.T., FDA

PANEL DISCUSSION: NEW CONSEQUENCES OF IMPROVED CANCER DIAGNOSTICS FOR TREATMENT AND CHEMOPREVENTION
Moderator: **James Crowell,** Ph.D., D.A.B.T., NCI

POSTER SESSIONS

WEDNESDAY, AUGUST 30

PLENARY SESSION: GENOMICS AND PROTEOMICS
Chairperson: **Eric A. G. Blomme**, D.V.M., Ph.D., D.A.C.V.P., Abbott Laboratories

PLENARY SESSION: FRONTIERS OF DRUG DISCOVERY AND DEVELOPMENT
Chairperson: **James A. Radosevich**, Ph.D., Professor, UIC

SPECIAL SYMPOSIA: TRANSLATIONAL RESEARCH IN ORGAN-SPECIFIC CANCERS
Moderators: **Robert H. Costa**, Ph.D. Professor UIC; **Gail Prins**, Ph.D. Professor UIC; **Alexander Lyubimov,** Ph.D., M.D., D.A.B.T., TRL, UIC; **Faith Davis**, Ph.D. Professor, UIC

POSTER SESSIONS

THURSDAY, AUGUST 31

MORNING MINI-SYMPOSIA and POSTER SESSIONS

More information about the Conference Program and Courses can be found at the conference website: http://www.uic.edu/labs/tox/frontiers

PRE-CONFERENCE COURSES

COURSE I: TOXICOLOGY IN DRUG DEVELOPMENT

AUGUST 26 - 27

Alex Lyubimov (Chairperson), Director, TRL, UIC and **Wanda M. Haschek-Hock** (Co-chair), UIUC

General Principles of Toxicology in Drug Development, **Alex Lyubimov**

Drug Development: Role of Toxicology and Toxicokinetics, **Ihor Bekersky**

Laboratory Animal Science Issues that Impact Rodent Pharmacology/Toxicology, **Jeff Everitt**

Early Preclinical Development in Support of Drug Discovery, **Glen Cantor**

Immunotoxicity, **Raj Krishnaraj**

Biotransformation of Toxic Chemicals, **Richard D. Minshall**

Pharmacokinetics, **Stacy Shord**

Clinical Toxicology, **Jerrold B. Leikin**

Efficacy, Clinical Trials and Post Market Surveillance, **D. Reid Patterson**

Safety Pharmacology, **Shayne Gad**

Toxicologic Pathology, **Wanda Haschek-Hock**

COURSE II: FUNDAMENTALS OF DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY

AUGUST 26 - 27

Ronald Hood (Chairperson), Ronald D. Hood & Associates

Comparative Embryology & Placentation of the Rat, Mouse and Rabbit, **John DeSesso**

Principles of Developmental Toxicology, **Edward Carney**

Study Designs for Developmental Toxicology, **Rochelle Tyl**

Interpretation of Data from Developmental Toxicity Studies, **Ronald Hood**

Study Designs for Male and Female Reproductive Toxicity Testing, **Ray York**

An Introduction to Female Reproductive Toxicity Testing and Interpretation of Data, **Robert Parker**

An Introduction to Male Reproductive Toxicity Testing and Interpretation of Data, **Donald Waller**

Use of Toxicokinetics in Planning Developmental Toxicity Studies and Toxicity Data Interpretation, **Gina Pastino**

An Introduction to Non-clinical Juvenile Toxicity Testing, **Melissa Beck**

Statistical Analysis of Developmental and Reproductive Toxicity Data, **Robert Holson**

Developmental and Reproductive Toxicity Risk Assessment – The USFDA Perspective, **Wafa Harrouk**

LODGING / LOCATION / REGISTRATION

Renaissance Chicago Hotel
One West Wacker Drive
Chicago IL 60601
Toll-Free: (800) 266-9432 or (312) 795-3361
Online Hotel Reservations for the Conference can be accessed on the conference website: www.uic.edu/labs/tox/frontiers

This conference and the pre-conference courses will be held at **The Renaissance Chicago Hotel.** Conveniently located in the heart of downtown Chicago, on the corner of State Street and Wacker Drive, this beautiful first-class venue overlooks the Chicago River. Chicago attractions that are just blocks away include the Art Institute, shopping on the Magnificent Mile, the Museum Campus, the downtown theater district and Chicago's lakefront.

A special rate of $169.00 per night plus tax has been arranged. To take advantage of this special rate you must be booked before **June 24, 2006,** after which the special rate will not be guaranteed. Space is limited, so we recommend booking the hotel sooner rather than later.

REGISTRATION FEES AND DEADLINES

CONFERENCE FEES August 28 – 31	**Full Fee**	**Student Fee**
Early Registration Received by May 15	$500	$350
Regular Registration May 16 – July 15	$550	$400
Late Registration After July 15	$650	$450

PRE-CONFERENCE COURSE FEES August 26 – 27	**Participants from Industry**	**Participants from Government/Academia**
Regular Registration Received by July 15	$895	$500
Late Registration After July 15 (as space allows)	$995	$600

Conference registration fees include access to all conference sessions, a welcoming reception, and refreshments. Registrants will also receive a special issue of **Chemico-Biological Interactions** with peer-reviewed presentations.

Pre-conference course fees include two breakfasts, one lunch, refreshments, and course materials. Registrants for course II will also receive a book titled, *Developmental and Reproductive Toxicology, a Practical Approach*, Ronald D. Hood, Editor, CRC Press, 2005.

Visit the conference web site for additional information

TO REGISTER

Go to our Conference Website: **www.uic.edu/labs/tox/frontiers**

UIC UNIVERSITY OF ILLINOIS AT CHICAGO

College of Medicine

Department of Pharmacology

Toxicology Research Laboratory

In collaboration with leading scientists of the **NCI, NIAID** and **FDA**

ANNOUNCES

2006 INTERNATIONAL CONFERENCE

FRONTIERS OF PHARMACOLOGY AND TOXICOLOGY:

Addressing Translational Research in Efficacy and Safety of New Medicines

August 28 – 31, 2006

The Renaissance Chicago Hotel, Chicago, Illinois

ALSO OFFERING TWO PRE-CONFERENCE COURSES

Toxicology in Drug Development *and*

Fundamentals of Developmental and Reproductive Toxicology

August 26 – 27, 2006

UIC UNIVERSITY OF ILLINOIS AT CHICAGO
Department of Pharmacology (M/C 868)
Toxicology Research Laboratory
835 S. Wolcott, E403 MSB
Chicago IL 60612

Non-Profit Org.
U.S. Postage
PAID
Chicago, IL
Permit No. 4860